NCT01096056View on ClinicalTrials.gov

Trial to Evaluate the Safety and the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Healthy Children

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 5, 2010

Primary Completion Date

December 13, 2010

Study Completion Date

December 13, 2010

Conditions
Influenza
Interventions
BIOLOGICAL

Influenza vaccine GSK2186877A formulation 1

Intramuscular administration, 2 doses

BIOLOGICAL

Influenza vaccine GSK2186877A formulation 2

Intramuscular administration, 1 dose

BIOLOGICAL

Fluarix

Intramuscular administration, 1 dose

Trial Locations (1)

41013

GSK Investigational Site, Seville

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY